Core Laboratories Inc.
CLB
$13.15
-$0.03-0.23%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.60% | -5.51% | 22.63% | 24.98% | -25.31% |
| Total Depreciation and Amortization | -0.88% | -2.03% | -3.42% | -4.47% | -4.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 792.69% | 266.93% | -120.33% | -80.13% | -3.89% |
| Change in Net Operating Assets | -188.29% | -292.89% | -14.17% | 225.47% | 180.06% |
| Cash from Operations | -40.30% | -34.33% | -9.97% | 29.60% | 71.76% |
| Capital Expenditure | -17.31% | -11.98% | -34.57% | -23.95% | -18.66% |
| Sale of Property, Plant, and Equipment | 38.10% | 73.73% | 215.32% | 235.58% | 137.78% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.46% | 115.99% | 110.60% | 152.36% | 73.74% |
| Cash from Investing | -61.26% | 65.11% | 61.41% | 39.81% | 36.77% |
| Total Debt Issued | 134.88% | 9.09% | -16.00% | -58.41% | -77.60% |
| Total Debt Repaid | -37.50% | 23.17% | 24.72% | 52.03% | 62.26% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -97.71% | -134.19% | -571.27% | -346.60% | -224.45% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.91% | 0.37% | 0.11% | -0.21% | -0.37% |
| Other Financing Activities | -894.44% | -152.90% | 2.10% | 95.45% | 95.57% |
| Cash from Financing | 41.26% | 31.99% | 3.45% | 15.02% | -62.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -90.10% | -12.19% | -14.47% | 258.57% | 624.34% |